About Us

Zürich, Switzerland  ·  Est. 1998

Precision Peptide Science.
Born in Switzerland.

For over two decades, Zürich BioGenix has operated at the frontier of synthetic peptide research — combining Swiss manufacturing precision with rigorous biochemical standards to support the global scientific community.

26+
Years of Research
>99%
HPLC Purity
500+
Peptide Compounds
40+
Countries Served
Our Origin

Founded at the crossroads of science and the Alps

Zürich BioGenix was established in 1998 by a team of biochemists and pharmacologists based at the University of Zürich, during a period when solid-phase peptide synthesis (SPPS) was transitioning from academic laboratories into a commercially viable discipline.

The founding vision was clear: build a vertically integrated peptide synthesis company rooted in Swiss scientific culture — one that would meet the exacting standards demanded by pharmaceutical researchers, academic institutions, and independent laboratories worldwide. Zürich's unique concentration of biomedical talent, combined with Switzerland's world-class regulatory infrastructure, made it the natural home for that ambition.

The name is no coincidence. A Swiss life sciences entity bearing a kindred name — formerly operating from Christoph Merian-Ring 29a, 4153 Reinach, Switzerland — laid the groundwork: years of pharmaceutical trade, European networks, and regulatory experience. When that chapter closed, the knowledge did not disappear. Zürich BioGenix was built to carry it forward: same scientific heritage, 21st-century technology, new ambitions.

Why Switzerland

The Greater Zürich Advantage

Switzerland has long been synonymous with precision engineering and pharmaceutical excellence. The Greater Zürich Area — home to ETH Zürich, the University of Zürich, and a dense network of life sciences companies — provides an unparalleled ecosystem for cutting-edge biochemical research.

The region's political stability, internationally respected IP framework, and proximity to Europe's major research institutions give Zürich BioGenix a structural advantage in sourcing talent, maintaining regulatory compliance, and building partnerships with the institutions that drive global peptide research forward.


Company History

Two decades of continuous advancement

1998 — Foundation
Established in Zürich
Zürich BioGenix is founded by a group of biochemists from the University of Zürich with a mandate to commercialize high-purity peptide synthesis for research applications. Initial focus: structural peptides and receptor-binding ligands.
2003 — Scale-Up
Purpose-built synthesis facility opens
The company commissions its first purpose-built SPPS (solid-phase peptide synthesis) production facility, enabling multi-gram synthesis under GMP-aligned conditions. HPLC purity benchmarks raised to >98% across the product catalogue.
2008 — Expansion
International research partnerships
Formal research supply agreements established with academic institutions in Germany, Austria, the Netherlands, and the UK. The peptide catalogue expands to over 200 compounds, with dedicated growth hormone peptide and neuropeptide lines.
2014 — Innovation
Mass spectrometry QC integration
Each batch gains mandatory LC-MS (liquid chromatography–mass spectrometry) verification alongside HPLC analysis. Certificate of Analysis documentation standardised across all product lines — a significant commitment to analytical transparency.
2019 — Digital
Direct-to-researcher platform launched
Zürich BioGenix launches its direct research supply platform, enabling independent laboratories and academic researchers to source verified, compounds with available COA documentation, without institutional procurement barriers.
2024 — Today
Over 500 compounds, 40+ markets
A catalogue of more than 500 research peptides, with full analytical documentation available to researchers in over 40 countries. Purity standards maintained at >99% HPLC across all flagship peptide lines.

Our Principles

What drives every synthesis run

⚗️

Analytical Rigour

Every batch undergoes HPLC and LC-MS analysis before release. Our Certificates of Analysis are not formalities — they are the product of instruments, not approximations. We publish what we measure.

🔬

Research Integrity

All products are supplied exclusively for in-vitro and laboratory research. We exist to support reproducible science, which means supply chains built on documentation, not trust alone.

🏔️

Swiss Manufacturing

Synthesised and quality-controlled in Zürich. Swiss manufacturing standards carry a global reputation for a reason — and that reputation is embedded in every vial we dispatch.

📋

Full Documentation

Certificate of Analysis, HPLC chromatogram, mass spectrum, and batch records are available upon request. Researchers need to trust their reagents — and trust is built on data.

🌡️

Cold Chain Standards

Lyophilised peptides are temperature-sensitive. Our logistics protocols maintain cold-chain integrity from synthesis through to delivery, protecting compound stability at every stage.

🔗

Scientific Partnership

We view our relationship with the research community as collaborative, not transactional. Our team includes active biochemists who understand the downstream requirements of the work our compounds support.

Quality Standards HPLC >99% Purity LC-MS Verified COA per Batch Lyophilised & Stable Cold Chain Shipping GMP-Aligned Synthesis
"Switzerland's concentration of biochemical expertise, its tradition of precision manufacturing, and its position at the centre of European science make it uniquely suited to the demands of high-purity peptide production. We did not choose Zürich by accident — we chose it because the standard it demands is the standard we want to hold ourselves to."
— Dr. M. Steiner, Head of Synthesis, Zürich BioGenix

Our Base

Zürich — the science capital of Switzerland

The Greater Zürich Area is home to ETH Zürich (consistently ranked among the world's top 10 universities), the University of Zürich, and a thriving ecosystem of biotech, pharma, and life science companies including Roche, Novartis, and hundreds of specialist research-stage firms.

This concentration of expertise creates a talent density that directly benefits our synthesis operations — from senior analytical chemists to regulatory consultants and cold-chain logistics specialists. Zürich is not simply where we are based. It is why our work is possible at the level we demand.

Zürich, Switzerland
47.3769° N, 8.5417° E

Ready to support your research?

Browse our catalogue of >500 research-grade peptides — all synthesised in Zürich, verified by HPLC and LC-MS, and shipped with full Certificate of Analysis documentation.

Explore the Catalogue

Registered Address

Christoph Merian-Ring 29a
4153 Reinach, Switzerland

Operations

Greater Zürich Area
Switzerland